Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTMX NASDAQ:DSGN NASDAQ:ENTX NYSE:MBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$1.99-0.5%$2.20$0.40▼$3.10$329.83M2.182.62 million shs3.35 million shsDSGNDesign Therapeutics$5.86-2.8%$4.83$2.60▼$7.77$343.40M1.61166,020 shs114,313 shsENTXEntera Bio$1.83+1.7%$1.94$1.50▼$2.79$82.19M1.6972,865 shs124,893 shsMBXMBX Biosciences$10.87+0.4%$13.05$4.81▼$27.50$363.82MN/A330,141 shs392,315 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics0.00%-12.28%+4.71%-18.70%+62.60%DSGNDesign Therapeutics0.00%-6.51%+13.13%+55.81%+8.84%ENTXEntera Bio0.00%-12.62%-10.00%-10.00%-9.55%MBXMBX Biosciences0.00%-6.23%-26.43%+3.14%+1,082,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$1.99-0.5%$2.20$0.40▼$3.10$329.83M2.182.62 million shs3.35 million shsDSGNDesign Therapeutics$5.86-2.8%$4.83$2.60▼$7.77$343.40M1.61166,020 shs114,313 shsENTXEntera Bio$1.83+1.7%$1.94$1.50▼$2.79$82.19M1.6972,865 shs124,893 shsMBXMBX Biosciences$10.87+0.4%$13.05$4.81▼$27.50$363.82MN/A330,141 shs392,315 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics0.00%-12.28%+4.71%-18.70%+62.60%DSGNDesign Therapeutics0.00%-6.51%+13.13%+55.81%+8.84%ENTXEntera Bio0.00%-12.62%-10.00%-10.00%-9.55%MBXMBX Biosciences0.00%-6.23%-26.43%+3.14%+1,082,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTMXCytomX Therapeutics 3.00Buy$5.75188.94% UpsideDSGNDesign Therapeutics 0.00N/AN/AN/AENTXEntera Bio 4.00Strong Buy$10.00446.45% UpsideMBXMBX Biosciences 3.00Buy$37.63246.14% UpsideCurrent Analyst Ratings BreakdownLatest ENTX, CTMX, DSGN, and MBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/11/2025ENTXEntera BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/5/2025MBXMBX BiosciencesMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$38.007/31/2025CTMXCytomX TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.007/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$38.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTMXCytomX Therapeutics$138.10M2.38$0.36 per share5.53($0.01) per share-199.00DSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/AENTXEntera Bio$166K503.39N/AN/A$0.23 per share7.96MBXMBX BiosciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTMXCytomX Therapeutics$31.87M$0.563.55N/AN/A34.04%158.70%36.04%11/6/2025 (Estimated)DSGNDesign Therapeutics-$49.59M-$1.12N/AN/AN/AN/A-27.15%-26.07%11/6/2025 (Estimated)ENTXEntera Bio-$9.54M-$0.26N/AN/AN/A-4,525.11%-77.75%-68.13%11/14/2025 (Estimated)MBXMBX BiosciencesN/A-$4.54N/AN/AN/AN/AN/AN/AN/ALatest ENTX, CTMX, DSGN, and MBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025ENTXEntera Bio-$0.11-$0.06+$0.05-$0.06N/AN/A8/7/2025Q1 2025DSGNDesign Therapeutics-$0.32-$0.34-$0.02-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTMXCytomX TherapeuticsN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTMXCytomX TherapeuticsN/A4.204.20DSGNDesign TherapeuticsN/A25.1325.13ENTXEntera BioN/A10.4710.47MBXMBX BiosciencesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTMXCytomX Therapeutics67.77%DSGNDesign Therapeutics56.64%ENTXEntera Bio14.11%MBXMBX BiosciencesN/AInsider OwnershipCompanyInsider OwnershipCTMXCytomX Therapeutics6.60%DSGNDesign Therapeutics23.50%ENTXEntera Bio10.38%MBXMBX Biosciences52.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTMXCytomX Therapeutics170164.91 million154.03 millionOptionableDSGNDesign Therapeutics4056.95 million43.57 millionOptionableENTXEntera Bio2045.66 million40.92 millionOptionableMBXMBX Biosciences3633.59 millionN/AN/AENTX, CTMX, DSGN, and MBX HeadlinesRecent News About These CompaniesWoodline Partners LP Has $6.48 Million Position in MBX Biosciences, Inc. $MBXSeptember 15 at 3:59 AM | marketbeat.com133,113 Shares in MBX Biosciences, Inc. $MBX Purchased by Exome Asset Management LLCSeptember 11, 2025 | marketbeat.comComparing MBX Biosciences (MBX) & Its RivalsSeptember 11, 2025 | americanbankingnews.comMBX Biosciences, Inc. $MBX Shares Acquired by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comMBX Biosciences, Inc. (NYSE:MBX) Given Consensus Rating of "Buy" by BrokeragesSeptember 8, 2025 | marketbeat.comWalleye Capital LLC Purchases New Position in MBX Biosciences, Inc. $MBXSeptember 7, 2025 | marketbeat.comJump Financial LLC Purchases Shares of 28,996 MBX Biosciences, Inc. $MBXSeptember 7, 2025 | marketbeat.comMBX Biosciences, Inc.: MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of ObesitySeptember 6, 2025 | finanznachrichten.deMBX Biosciences doses first participant in Phase 1 trial of MBX 4291September 4, 2025 | msn.comMBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of ObesitySeptember 4, 2025 | globenewswire.comMPM Bioimpact LLC Purchases Shares of 1,132,950 MBX Biosciences, Inc. $MBXSeptember 4, 2025 | marketbeat.comAffinity Asset Advisors LLC Buys Shares of 175,000 MBX Biosciences, Inc. $MBXAugust 28, 2025 | marketbeat.comWellington Management Group LLP Sells 271,118 Shares of MBX Biosciences, Inc. $MBXAugust 28, 2025 | marketbeat.comMBX Biosciences Insiders Added US$579.8k Of Stock To Their HoldingsAugust 20, 2025 | uk.finance.yahoo.comMBX Biosciences Submits IND for Once-Monthly Obesity DrugAugust 20, 2025 | finance.yahoo.comJefferies Financial Group Initiates Coverage on MBX Biosciences (NYSE:MBX)August 17, 2025 | marketbeat.comA Glimpse of MBX Biosciences's Earnings PotentialAugust 14, 2025 | benzinga.comMBX Biosciences Reports Progress and Financial StabilityAugust 11, 2025 | tipranks.comMBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsAugust 7, 2025 | globenewswire.comMizuho Initiates Coverage of MBX Biosciences (MBX) with Outperform RecommendationAugust 5, 2025 | msn.comMBX Biosciences Inc. (MBX) Stock Price Today - WSJAugust 2, 2025 | wsj.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENTX, CTMX, DSGN, and MBX Company DescriptionsCytomX Therapeutics NASDAQ:CTMX$1.99 -0.01 (-0.50%) Closing price 04:00 PM EasternExtended Trading$2.00 +0.01 (+0.50%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Design Therapeutics NASDAQ:DSGN$5.86 -0.17 (-2.82%) Closing price 04:00 PM EasternExtended Trading$5.86 0.00 (0.00%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Entera Bio NASDAQ:ENTX$1.83 +0.03 (+1.67%) Closing price 04:00 PM EasternExtended Trading$1.82 -0.02 (-0.82%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.MBX Biosciences NYSE:MBX$10.87 +0.04 (+0.37%) Closing price 04:00 PM EasternExtended Trading$10.74 -0.14 (-1.24%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
